-
Company Insights
New![]()
Innovation and Patenting activity of Editas Medicine Inc Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Editas Medicine Inc Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
New![]()
Net Present Value Model: Editas Medicine Inc’s EDIT-301
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Bristol-Myers Squibb Co’s Farletuzumab Ecteribulin
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GDA-201 in Relapsed Multiple Myeloma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. GDA-201 in Relapsed Multiple Myeloma Drug Details: GDA-201 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GDA-201 in Refractory Multiple Myeloma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. GDA-201 in Refractory Multiple Myeloma Drug Details: GDA-201 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – EDIT-301 in Beta Thalassaemia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.EDIT-301 in Beta Thalassaemia Drug Details:EDIT-301 is under development for the treatment of beta-thalassemia and sickle...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – EDIT-301 in Sickle Cell Disease
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. EDIT-301 in Sickle Cell Disease Drug Details: EDIT-301 is under development for the treatment of...
-
Thematic Analysis
New![]()
Synthetic Biology – Thematic Intelligence
Synthetic Biology Thematic Report Overview Synthetic biology is commonly abbreviated to synbio. It involves the manipulation of genetic material to enhance specific characteristics or, conversely, stifle them. The ability to perform this manipulation quickly, precisely, and at a low cost has the potential to impact numerous sectors. From developing environmentally friendly luxury materials to novel cancer therapeutics and even the use of DNA as a new form of data storage, the forthcoming field of synbio unlocks several new realms of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Devimistat in Sarcomas
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Devimistat in Sarcomas Drug Details:Devimistat (CPI-613) is under development for the treatment of Burkitt lymphoma or...
-
Track & Monitor
![]()
Innovation in pharma: CRISPR nucleases
Why settle for outdated information when you can stay ahead of the curve with our comprehensive report? Our team of industry experts has meticulously researched and analyzed the latest trends, innovations, and emerging technologies in the pharma industry’s CRISPR nucleases innovations. By leveraging our report, you'll gain invaluable insights that can revolutionize your business strategies and give you a competitive edge. Why Choose Our Report? Unparalleled Expertise: Our research team consists of seasoned analysts with deep knowledge and experience in...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.